Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

2 results

  • Topics : Breast diseases
  • Active substance : iopromide
Filter
Topic
  • Economics and public health (2)
  • Plus ...
    • Screening, prevention (2)
  • Diagnostic and therapeutic techniques (2)
  • Plus ...
    • Diagnostic techniques and procedures (2)
    • Plus ...
      • Medical imaging (2)
    • Drug therapy (1)
  • Diseases and conditions (2)
  • Plus ...
    • Breast diseases (2)
    • Plus ...
      • Breast cancers (2)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Drugs, devices and medical acts (2)
  • Plus ...
    • Medicine (1)
    • Health technology assessment (1)
Date
  • Last five years (1)
  • This year (1)
Manufacturer
  • inconnu (1)
  • industriels (1)
Language
  • Français (2)
Active substance
  • alcool (1)
  • cuivre (1)
  • gadobutrol (1)
  • gadodiamide (1)
  • gadolinium (1)
  • hydrocortisone (1)
  • iobitridol (1)
  • iode (1)
  • iodixanol (1)
  • iohexol (1)
  • iopamidol (1)
  • iopromide (2)
  • ioversol (1)
  • trastuzumab (1)
 More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 2 results

  • ULTRAVIST (iopromide)

    Medicine - Posted on 9/10/2024
    Add to my selection

  • Usefulness of contrast-enhanced mammography in breast cancer diagnosis strategy - INAHTA Brief

    Health technology assessment - Posted on 22/11/2021 - Mis à jour le 22/11/2021
    Download document
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
crTYbG3Mqg994szW